We are live on ! Find out more
CADX

CADENCE PHARMACEUTICALS, INC COM STK
CADX

Delisted

CADX was delisted on the 18th of March, 2014.

Back to rankings

0 hedge funds and large institutions have $0 invested in CADENCE PHARMACEUTICALS, INC COM STK in 2014 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 3 → 0 (-3)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $3.77M → $0 (-$3.77M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
–
Holders Change
-3
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
OP
Omni Partners
United Kingdom
-$3.5M
2
Citigroup
Citigroup
New York
-$183K
3
BIT
BlackRock Institutional Trust
California
-$86K
Name Holding Trade Value Shares
Change 		Change in
Stake
OP
1
Omni Partners
United Kingdom
– -$3.5M -250,000 Closed
Citigroup
2
Citigroup
New York
– -$183K -13,052 Closed
BIT
3
BlackRock Institutional Trust
California
– -$86K -6,178 Closed

CADX Hedge Fund Activity: Q2 2014 in Review

0 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in CADENCE PHARMACEUTICALS, INC COM STK (CADX) for Q2 2014, worth a combined $0 — down 100% from $3.77M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CADX and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Omni Partners, exiting entirely with an estimated $3.5M sold.

  • 0 institutional investors held CADENCE PHARMACEUTICALS, INC COM STK (CADX) as of Q2 2014, down from 3 in Q1 2014.
  • Funds reported $0 of CADENCE PHARMACEUTICALS, INC COM STK stock for Q2 2014, down 100% quarter-over-quarter.
  • 0 funds opened new CADENCE PHARMACEUTICALS, INC COM STK positions in Q2 2014 and 3 closed out, a net change of -3 holders.
  • The largest CADENCE PHARMACEUTICALS, INC COM STK seller in Q2 2014 was Omni Partners, an estimated $3.5M sold.

Based on aggregated 13F filings for Q2 2014.